Updated health economic analysis Palbociclib

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.

 

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

Kommentare: 0

Fr

16

Apr

2021

Vorbereitungen Rûzje Wyn 2021

Sa

24

Okt

2020

Kroatien 2020

Sa

23

Mai

2020

Arc-en-ciel

Thanks to Saskia and Patrick for these recordings

mehr lesen

Sa

21

Dez

2019

Newest Publication

Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.

Panje CM, Putora PM, Hundsberger T, Hottinger AF, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K.

Swiss Med Wkly. 2019 Dec 2;149:w20153. doi: 10.4414/smw.2019.20153. eCollection 2019 Dec 2.